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Abstract
Background: High hemagglutination inhibition (HAI) and neuraminidase inhibition (NAI) titers are generally
associated with reduced influenza risk. While repeated influenza vaccination reduces seroresponse, vaccine
effectiveness is not always reduced.
Methods: During the 2007-2008 influenza season, a randomized, placebo-controlled trial (FLUVACS) evaluated the
efficacies of live-attenuated (LAIV) and inactivated influenza vaccines (IIV) among healthy adults aged 18-49 in
Michigan; IIV vaccine efficacy (VE) and LAIV VE against influenza disease were estimated at 68% and 36%. Using the
principal stratification/VE moderation framework, we analyzed data from this trial to assess how each VE varied by HAI
or NAI responses to vaccination observed for vaccinated individuals and predicted counterfactually for placebo
recipients. We also assessed how each VE varied with pre-vaccination/baseline variables including HAI titer, NAI titer,
and vaccination history.
Results: IIV VE appeared to increase with Day 30 post-vaccination HAI titer, albeit not significantly (p=0.20 and
estimated VE 14.4%, 70.5%, and 85.5% at titer below the assay lower quantification limit, 512, and 4096 (maximum)).
Moreover, IIV VE increased significantly with Day 30 post-vaccination NAI titer (p=0.040), with estimated VE zero at titer
10 and 92.2% at highest titer 640. There was no evidence that fold-change in post-vaccination HAI or NAI titer
associated with IIV VE (p=0.76, 0.38). For LAIV, there was no evidence that VE associated with post-vaccination or
fold-rise HAI or NAI titers (p-values >0.40). For IIV, VE increased with increasing baseline NAI titer in those previously
vaccinated, but VE decreased with increasing baseline NAI titer in those previously unvaccinated. In contrast, for LAIV,
VE did not depend on previous vaccination or baseline HAI or NAI titer.
Conclusions: Future efficacy trials should measure baseline and post-vaccination antibody titers in both vaccine and
control/placebo recipients, enabling analyses to better elucidate correlates of vaccine- and natural-protection.
Trial registration: ClinicalTrials.gov NCT00538512. October 1, 2007.
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Background
Influenza hemagglutinin (HA) binds to sialic acid recep-
tors on target cells and is the main target of neutralizing
antibodies [1]. As such, HA is the primary standard-
ized antigen in the inactivated influenza vaccine (IIV)
[2]. Serum levels of anti-HA antibodies are measured by
the hemagglutination inhibition (HAI) assay. When assay
targets are well matched to circulating viruses, there is
generally a clear relationship between increasing HAI titer
and decreasing infection risk [3–9]; however, some indi-
viduals acquire infection or experience influenza disease
despite high HAI titers [4, 10–12] or seroconversion [12].
Neuraminidase (NA) is also present in most influenza
vaccines, albeit at nonstandardized concentrations [13].
As measured by neuraminidase inhibition (NAI) assays,
anti-NA antibodies play an independent role in protec-
tion from influenza disease and/or in reducing influenza
disease severity [14, 15].
Antigenic drift [16–18] necessitates annual evaluation
of influenza vaccine composition [19]. To optimize the
immune response to strains most likely to cause infection,
annual influenza vaccination is currently recommended
in the United States for all individuals aged ≥6 months
(unless contraindicated) [20]. However, reduced serore-
sponse can occur after repeated influenza vaccination
[21–26]. While this suggests that repeated vaccination
may have diminishing benefit to protect against influenza
infection or disease, reduced vaccine effectiveness with
repeated vaccination has only been observed in some,
primarily A(H3N2) predominant, seasons [27–35]. These
apparently inconsistent results could be explained by the
degree of antigenic relatedness between vaccine and cir-
culating viral strains [36, 37].
The principal stratification/vaccine efficacy (VE) mod-
eration framework [38–40] (hereafter called the “VEmod-
eration” framework) is a statistical method for assess-
ing how vaccine efficacy varies over subgroups defined
by biomarkers measuring immune responses in vacci-
nees. This framework requires data from a randomized-
controlled trial with sufficient endpoint cases and ample
immune response measurements from vaccinees in cases
and non-cases, as well as variables measured at base-
line in both vaccine and placebo recipients (cases and
non-cases) that are predictive of post-vaccination immune
responses. The latter requirement enables the baseline
immunogenicity predictor (BIP)-augmented efficacy trial
design [39, 40] that predicts the immune response to
the vaccine that placebo recipients would have had had
they been vaccinated, allowing estimation of the VE-by-
postvaccination-titer curve. Using this framework, fold-
rise in anti-varicella zoster virus (VZV) titers was shown
to be strongly associated with VE against herpes zoster
disease, whereas post-vaccination titers at 6 weeks were
not, implying that baseline titers must be measured to
predict VE [41]. This framework also showed that post-
vaccination neutralization titers were strongly associated
with VE against virologically confirmed dengue [42]. We
applied this framework to data collected as part of a
randomized, placebo-controlled trial of the absolute and
relative efficacies of IIV and live-attenuated influenza
vaccine (LAIV) [43] to assess how VE against laboratory–
confirmed influenza disease varied across subgroups
defined by their HAI or NAI responses to vaccination. We
also studied how VE varied with baseline/pre-vaccination
data on HAI, NAI, and relevant clinical variables.
Methods
Study design and intervention
The FLUVACS trial enrolled healthy adults aged 18 to 49
years, excluding individuals with a health condition for
which vaccination was specifically recommended (includ-
ing being immunocompromised or being older than 49
years) or for which either vaccine was contraindicated.
Participants were recruited from October to November
2007 and randomly assigned to receive IIV (Fluzone,
Sanofi Pasteur), LAIV (FluMist, MedImmune), or saline
placebo. Surveillance for influenza-like illness was carried
out from November 2007 through April 2008. Overall IIV
and LAIV efficacy were 68% and 36%, respectively [43].
Influenza endpoint, cases and controls
The study endpoint was laboratory–confirmed influenza
disease, defined as symptomatic acute respiratory illness
subsequently confirmed by RT-PCR influenza virus iden-
tification [43]. Participants with an observed endpoint are
referred to as cases and participants completing follow-
up (with a post-season sample) without experiencing the
endpoint are referred to as controls.
For antibody response measurements, serum samples
were collected at Day 0 (immediately before interven-
tion administration), Day 30 (approximately), and at the
influenza season conclusion (approximately 4 months
later). HAI titers were measured in a subset of all par-
ticipants (including participants in each treatment arm)
consisting of all cases and a random sample of partici-
pants for whom all 3 serum samples were available [14].
NAI titers were measured in all cases and in a smaller
sub-sample of controls [14].
HAI and NAI titer variables
The HAI assay measures the highest dilution of serum
that prevents influenza virus-induced hemagglutination
of erythrocytes [44]. The reciprocal of this dilution was
defined as the HAI titer. In the lectin-based NAI assay
[45], the reciprocal of the highest dilution of serum that
inhibits NA activity at least 50% compared to control wells
was defined as the NAI titer. Titers below the lower limit
of quantification for both assays were set to half this value
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[14]. For HAI titers in graphs, log2(x) for x = 0, 1, 2, etc.
corresponds to titer (2x)∗4, and for NAI titers log2(x) cor-
responds to titer (2x)∗5. Fold-rise in HAI or NAI titer was
defined as (Day 30 titer)/(Day 0 titer).
Vaccine efficacy parameters
Overall vaccine efficacy (VE) for either vaccine versus
placebo was defined as the multiplicative reduction in the
probability of influenza disease occurrence:
VE = 1 − P(influenza disease|vaccine)
P(influenza disease|placebo) .
VE for a vaccinated subgroup defined by a fixed value s
of the Day 30 or fold-rise in titer was defined as
VE(s) = 1 − P(influenza disease|vaccine, titers)
P(influenza disease|placebo, titers) .
The critical feature of the VE moderation framework
is that the subgroup s is defined under assignment to
a vaccine group, which is observable for participants
actually assigned to a vaccine group, but is counterfac-
tual and hence missing for participants assigned to the
placebo group [39, 40, 46]. Implementation of this frame-
work for estimating VE over subgroups s requires predic-
tion of the missing counterfactual responses of placebo
recipients [41].
For studying the association of baseline variables with
VE, the VE parameter of interest is one minus the ratio
(vaccine/placebo) of the disease incidence in subgroups
defined by fixed values of the baseline variables.
Objectives
We investigated: (1) if VE varies by Day 0 HAI or NAI
titer and/or by other baseline clinical variables; (2) if VE
varies by fold-rise HAI titer and by fold-rise NAI titer;
(3) if VE varies by Day 30 HAI titer and by Day 30
NAI titer. Baseline clinical variables included age, sex,
race, and whether the individual self-reported ever having
received an influenza vaccine before (hereafter referred to
as “previously vaccinated”).
Statistical analysis
Boxplots and scatterplots with Spearman rank correla-
tions describe the Day 0, 30, and fold-rise HAI and NAI
titer distributions. These distributions were compared
across groups (treatment arms, vaccination history) using
Wilcoxon rank-sum tests, and across age levels by Spear-
man rank correlations.
Objective (1) was addressed by multivariable logistic
regression (with sandwich variance estimates) modeling
of how the risk of influenza outcome depended on titer
variables and clinical variables, which is valid under the
case-control sampling design [47]. Forward selection step-
wise regression based on Wald tests was used to select
best-fitting models.
Objectives (2) and (3) were addressed using the same
or similar statistical methods as in [41]. The influenza
disease endpoint was treated as a dichotomous out-
come (case vs. control); time-to-event methods would not
add value given all vaccinations were completed from
10/10/2007 to 11/09/2007, all influenza events occurred
between 1/10/2008 and 3/09/2008, and 96.4% of partici-
pants completed all scheduled visits in this year.
For Day 30 or fold-rise variables treated as quantitative
variables, the Juraska et al. method [48] was applied, which
was also used in [42]. We describe the method for Day 30
HAI titer; the same method is used swapping in Day 30
NAI titer, fold-rise HAI titer, and fold-rise NAI titer. This
method specifies a structural logistic regression model
P(Y (z)=1|S(z) = s,X = x)=expit (β0z+β1zS(z) + β2zX)
where Y (z) is the indicator of the influenza endpoint if
assigned treatment z, z = 0 (placebo) and z = 1 (vaccine),
expit(a) = exp(a)/(1 + exp(a)), S(z) is Day 30 HAI titer
if assigned treatment z (z = 0, 1), and X is the baseline
covariate age in years at enrollment. Inverse probability-
weighting is used in the logistic regression model is used
to account for the probabilities participants have the titer
data measured. The method incorporates an estimate of
the conditional density of S(1) given Sb and X, obtained
by nonparametric kernel smoothing with optimal band-
widths selected by likelihood cross-validation [49], where
Sb is Day 0 HAI titer. A main assumption of this method
is that the risk of Y (0) = 1 is conditionally independent
of S(1) given S(0) and X, which in our application states
that after accounting for age and the Day 30 HAI titer
if assigned placebo, Day 30 titer if assigned vaccine does
not contain additional information about influenza risk if
assigned placebo.
The method outputs point estimates of VE(s),
bootstrap-based 95% pointwise and simultaneous con-
fidence bands for VE(s), and a bootstrap-based 2-sided
p-value for testing whether VE(s) varies in s, for each of
the IIV and LAIV versus placebo.
For regression analyses of objectives (1)–(3), quantita-
tive response variables were analyzed on the log2 scale.
Analyses for objectives (2) and (3) were conducted using
the pssmooth R package available at CRAN [50].
Results
HAI and NAI titer data
The numbers of study participants by treatment group
and influenza disease case-control status, as well as by
Day 0 and Day 30 HAI and NAI titer data and previous
vaccination, are shown in Table 1. Of the IIV, LAIV, and
placebo groups, 279 of 813 (34.3%), 324 of 814 (39.8%),
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Table 1 HAI and NAI Titer Plus Previous Vaccination Data for the
Year-4 FLUVACS Study∗
HAI Titers NAI Titers
Treatment Group No. No. w/ Day 0
and Day 30
No. w/ Day 0
and Day 30
Placebo Total 325 125 92
Cases 30 30 29
Controls 295 95 63
LAIV Total 814 324 227
Cases 54 54 52
Controls 760 270 175
IIV Total 813 279 178
Cases 22 22 22
Controls 791 257 156
Placebo Total 136 48 42
Restrict Cases 15 15 15
EVERVAX=1∗∗ Controls 121 33 27
LAIV Total 307 135 92
Restrict Cases 26 26 24
EVERVAX=1 Controls 281 109 68
IIV Total 288 99 58
Restrict Cases 6 6 6
EVERVAX=1 Controls 282 93 52
Placebo Total 138 54 35
Restrict Cases 11 11 10
EVERVAX=0 Controls 127 43 25
LAIV Total 388 144 105
Restrict Cases 21 21 21
EVERVAX=0 Controls 367 123 84
IIV Total 388 128 93
Restrict Cases 13 13 13
EVERVAX=0 Controls 375 115 80
∗ In the third column, all participants with an observed influenza endpoint (Cases)
and all participants completing follow-up (with a post-season sample) without
experiencing the influenza endpoint (Controls) are included in the counts,
regardless of whether immunological data were measured. The remaining columns
include the subset of these participants with HAI or NAI titer measurements at Day 0
and Day 30. For each assay HAI and NAI, all participants either had both Day 0 and
Day 30 titers measured, or neither Day 0 and Day 30 titers measured. All participants
with NAI titers measured also had HAI titers measured. ∗∗EVERVAX is self-report of
ever having received a previous flu vaccine: 1 = yes, 0 = no
and 125 of 325 (38.5%) individuals had HAI titer data at
both time points. A subset of these also had NAI titer data
at both time points (178, 227, and 92 individuals, respec-
tively). Of the individuals with HAI and NAI titer data, 22,
52, and 29 (IIV, LAIV, and placebo) had the influenza dis-
ease endpoint. In these groups 676 of 813 (83.1%), 695 of
814 (85.4%), and 274 of 325 (84.3%) had data on previous
vaccination, of whom 42.6%, 44.2%, and 49.6% had been
previously vaccinated.
Boxplots of Day 0, Day 30, and fold-rise HAI and NAI
titers for each treatment group, stratified by case-control
status, are shown in Fig. 1. Day 0 HAI and NAI titers were
higher in controls than cases consistently across the three
groups. This pattern also occurred for Day 30 HAI and
NAI titers, with the difference between cases and con-
trols about the same for the two vaccines and greatest
for the placebo group. Fold-rises in HAI and NAI titers
were similar when comparing cases and controls across
the three treatment groups, with much greater variabil-
ity in fold-rise responses for the vaccine groups than the
placebo group. Day 30 vaccine responses were greater for
the IIV than the LAIV. Moreover, fold-rise was larger for
HAI compared to NAI.
Distributions and scatterplots of all pairs of Day 0, Day
30, and fold-rise HAI and NAI titer variables for each
of the two vaccine groups and for the set of vaccinees
with complete HAI and NAI data are shown in Additional
file 1: Figures S1 and S2; corresponding plots for the
placebo group are shown in Figure S3. For each assay there
were moderate-to-strong direct correlations between Day
0 titers with Day 30 titers and inverse correlations between
Day 0 titers with fold-rise titers, with Spearman rank cor-
relations for the IIV 0.47, 0.68, 0.66 and 0.57 between
(Day 0 HAI, Day 30 HAI), (Day 0 NAI, Day 30 NAI), (Day
0 HAI, fold-rise HAI), and (Day 0 NAI, fold-rise NAI),
respectively, compared to 0.81, 0.85, 0.53, and 0.36 for the
LAIV. The high correlation for Day 0 and Day 30 titers for
LAIV occurs because most participants did not have anti-
body response to vaccination. The reasonably strong cor-
relations between Day 0 and post-vaccination titers (Day
30, fold-rise) indicated that the baseline immunogenic-
ity predictor-based statistical methods for estimating the
VE(s) curves using the VE moderation framework could
be effectively applied, for each vaccine and each assay. For
the IIV, Day 0 titers were similarly predictive of Day 30
titers and of fold-rise titers, implying similar precision for
assessing how VE varied with Day 30 titers and with fold-
rise titers. In contrast, for the LAIVDay 0 titers weremore
predictive of Day 30 titers than fold-rise titers, implying
that Day 30 titers could be assessed as a correlate of VE
with more precision than fold-rise titers.
As shown in Fig. 2, baseline HAI titers were higher
(p < 0.001) in the previously vaccinated whereas previous
vaccination did not significantly associate with baseline
NAI titers (p = 0.16). In addition, baseline HAI titers
were inversely correlated with age among previously vac-
cinated participants (p < 0.001), but not among previ-
ously unvaccinated participants; moreover, baseline NAI
titer was not correlated with age regardless of previous
vaccination status (Fig. 2). We repeated these analyses
for Day 30 HAI and Day 30 NAI, for each treatment
arm (Additional file 1: Figures S4 and S5; Table S1).
There were no significant differences in Day 30 HAI or
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Fig. 1 Boxplots of Day 0, Day 30, and fold-rise HAI and NAI titers by treatment group (Placebo, LAIV, IIV) and influenza case-control outcome status.
Boxplots of HAI and NAI titers by treatment group and influenza case-control outcome status. Day 0 titers (top row), Day 30 titers (middle row), and
titer fold-rise (Day 30 / Day 0) are shown for participants assigned to placebo (left column), live attenuated influenza vaccine (middle column), or
inactivated influenza vaccine (right column)
Day 30 NAI titers by previous vaccination status within
any arm. Day 30 HAI titer decreased significantly with
age among the previously vaccinated in placebo recip-
ients and among previously vaccinated in the IIV arm.
Day 30 NAI titer decreased significantly with age among
both previously vaccinated and unvaccinated placebo
recipients.
Baseline covariates as correlates of vaccine efficacy against
influenza disease
Selected multivariable logistic regression models of VE
against influenza disease that were functions of the base-
line covariates Evervax (“previously vaccinated”), Day 0
HAI titers, Day 0 NAI titers, age, sex, and race are shown
in Table 2 (one final model for each vaccine). Only vari-
ables with 2-sided p < 0.05 in the multivariable model
were kept in the final model, except vaccination status
(Vacc) was kept. When an interaction term was added,
the main effects that made up the interaction were also
included in the model. These VE models were built upon
separate correlates of risk models for individual treatment
arms, in which we also tested for interactions between
quadratic associations of Day 0 HAI and Day 0 NAI titers
with influenza, as well as interactions between Evervax
and Day 0 HAI titer and between Day 0 HAI and Day
0 NAI titers with influenza, and found no statistically
significant evidence to add these terms to the models.
Results from Table 2 show that VE of LAIV was not
modified by any baseline variable. However, there was a
significant interaction between IIV, Evervax, and Day 0
NAI (p=0.006); this interaction means that VE as a func-
tion of Day 0 NAI titer differs for the Evervax Yes and
No subgroups. Figure 3 illustrates this three-way interac-
tion by plotting estimated VE of IIV as a function of Day
0 NAI titer for the previously vaccinated and the previ-
ously unvaccinated, showing that higher Day 0 NAI was
associated with increased VE in the previously vaccinated
(estimated VE 7% at titer below the assay lower quantifi-
cation limit and 57% at titer 40, p=0.23 for varying VE),
but with lower VE in the previously unvaccinated (esti-
mated VE 77% at titer below the assay lower quantification
limit and 0% at titer 40, p=0.007 for varying VE). Figure 4
shows how this result seems to be driven by the previ-
ously vaccinated in the placebo group, for which influenza
risk strongly decreases with Day 0 NAI titer. Results from
Table 2 also show a highly significant inverse association
between Day 0 HAI titers and influenza risk, without an
interaction with Evervax or IIV. Additional file 1: Table S2
shows results of separate logistic regression model fits to
each treatment arm.
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Fig. 2 Distributions of Day 0 HAI and NAI titers by previous vaccination status and age. for all three treatment groups combined. Small perturbations
are added to titer values to improve visibility. Spearman correlation coefficients r are shown in the scatterplots. Data shown are from all three
treatment groups combined. Small perturbations are added to titer values to improve visibility. Spearman correlation coefficients r are shown in the
scatterplots. For the HAI titer plots, 8192 means >4096 and 4 means <8 (the upper and lower limits of quantification of the HAI assay were 4096
and 8, respectively)
Day 30 and fold-rise HAI and NAI titers as correlates of
vaccine efficacy against influenza disease
Day 30 and Fold-Rise Correlates of IIV Efficacy.
Estimated IIV efficacy as a function of Day 30 HAI titers
in vaccinees and as a function of fold-rise in HAI titers
Table 2 Correlates of vaccine efficacy final logistic regression
models based on baseline/pre-vaccination variables
LAIV IIV
OR (95% CI) P OR (95% CI) P
Vacc 0.69 (0.38, 1.25) 0.224 0.05 (0.01, 0.28) 0.001
Evervax 0.70 (0.24, 2.05) 0.512 0.25 (0.03, 1.96) 0.189
Day 0 HAI 0.84 (0.74, 0.96) 0.007 0.71 (0.60, 0.84) 0.000
Day 0 NAI 0.60 (0.46, 0.78) 0.000 0.37 (0.20, 0.71) 0.002
Evervax:Day 0 NAI 1.69 (1.17, 2.43) 0.005 2.97 (1.30, 6.78) 0.010
Vacc:Evervax 16.81 (0.99, 284.65) 0.051
Vacc:Day 0 NAI 2.73 (1.31, 5.71) 0.008
Vacc:Evervax:Day 0 NAI 0.23 (0.08, 0.66) 0.006
∗All models adjust for age, sex and race at baseline. Vacc = 1 or 0 if assigned vaccine
or placebo; Evervax = 1 or 0 if self-reported ever having an influenza vaccination yes
or no; HAI and NAI titers are log base 2 transformed. ∗∗Entries for two-way
interactions (e.g., Vacc:Evervax) are ratios of odds ratios, and for three-way
interactions (Vacc:Evervax:Day 0 NAI) are ratios of ratios of odds ratios
in vaccinees, as well as the parallel results for NAI titers,
are shown in Fig. 5. The estimated VE curves assess VE
ranging over subgroups defined by a Day 30 biomarker
measuring response to vaccination that is observable in
vaccinees and a counterfactual that is predicted in placebo
recipients; the method accounts for uncertainty in this
prediction. Estimated VE increased with Day 30 HAI titer,
albeit with nonsignificant evidence for titer-varying VE
(p=0.20).
(Figure 5a). Moreover, estimated VE increased signifi-
cantly with Day 30 NAI titers (p=0.040), with estimated
VE above 80% at titers ≥ 160 and with estimated VE near
zero at titer 10 but with low precision at lowest titers ≤
20. Estimated VE was approximately constant with fold-
rise in HAI titers and with fold-rise in NAI titers, with
no evidence of titer-varying VE (p= 0.38, 0.76). We note
there is strong evidence of high VE for vaccine recipi-
ents with high postvaccination HAI or NAI titers, based
on the confidence bands that are well above 0, but there
is large uncertainty about VE (as indicated by the wide
confidence bands) for vaccine recipients with the lowest
postvaccination HAI or NAI titers.
Day 30 and Fold-Rise Correlates of LAIV Efficacy.
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(A) (B)
Fig. 3 VE of the IIV vaccine depends on baseline NAI titer differently among the previously vaccinated and previously unvaccinated. VE-by-Day-0
NAI titer plots are shown for the IIV vaccine in (a) the previously vaccinated vs (b) unvaccinated
For the LAIV (Fig. 6), there was no evidence for titer-
varying VE by Day 30 HAI titer or by Day 30 NAI titer,
(p=0.48, 0.94). There was also no evidence that fold-rise
in HAI titer (p=0.66) or in NAI titer (p=0.91) associated
with VE. The confidence bands generally include 0 for
all marker subgroups and for each of the four markers,
indicating limited precision in this study to learn about
modifiers of LAIV VE.
Discussion
Higher pre-vaccination/baseline HAI titers were observed
among the previously vaccinated than among the pre-
viously unvaccinated, while no difference in NAI titers
was observed. These findings suggest that NAI titers
decay faster than HAI titers after vaccination or are not
boosted as much by vaccination as HAI titers. The former
explanation is unlikely considering that post-vaccination
HAI and NAI titers have been observed to wane at similar
rates [21, 51], while the latter explanation is supported by
the fact that the NA concentration is not standardized in
currently licensed influenza vaccines.
There was no evidence that LAIV efficacy depended
on previous vaccination or baseline HAI or NAI titer.
In contrast, IIV efficacy was significantly modified by
previous vaccination and baseline NAI titers in an inter-
active way. In the previously vaccinated, estimated VE
was near zero for individuals NAI seronegative at base-
line and increased to about 75% for those with highest
baseline NAI titers, whereas in the previously unvacci-
nated the opposite pattern was observed, with estimated
Fig. 4 Evervax modifies the association between Day 0 NAI and influenza risk with decreasing strength in the placebo arm. The shaded area is the
pointwise 95% confidence region for the risk function among Evervax=NO in the placebo group. The slopes of the other three risk functions are not
significantly different from 0
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Fig. 5 Estimated IIV VE by Day 30 and fold-rise HAI and NAI titer variables. Estimated VE by a Day 30 HAI titer if assigned vaccine, b fold-rise in HAI
titer if assigned vaccine, c Day 30 NAI titer if assigned vaccine, d fold-rise in NAI titer if assigned vaccine. Each solid black line is the estimated VE by
the Juraska (2018) method [48]. Dashed and dot-dashed black lines are pointwise and simultaneous 95% confidence intervals, respectively. Each
dotted red line is the estimated overall VE. P-values shown are 2-sided p-values for effect modification
VE about 75% for baseline NAI seronegative individuals
and decreased to zero for those with baseline NAI titers
at 40 or higher. This result seems to be driven by the
placebo group, for which risk was not associated with
baseline NAI titers in the previously vaccinated but was
strongly inversely associated with baseline NAI titers in
the previously unvaccinated. One possible explanation of
this difference in risk profiles is that previously unvacci-
nated individuals with high baseline NAI titers represent
individuals with sustained/durable NAI responses, per-
haps obtained following natural infection, and there is
lower risk of influenza disease. In contrast, for previ-
ously vaccinated individuals, the subgroup with high Day
0 NAI titers is a mixture of two subgroups: individuals
who could have high NAI responses even without the pre-
vious vaccination, and individuals with a boosted NAI
response from the previous vaccination, where the risk
of influenza disease is not low. Alternatively, Day 0 NAI
titers may lose their ability to accurately mark natural
protection among individuals who have been previously
vaccinated. The finding that previously unvaccinated indi-
viduals with high pre-vaccination HAI or NAI titers were
unlikely to be protected by IIV may be related to multiple
layers of protection conferred through naturally acquired
immunity by prior influenza infection, operating not only
through humoral responses but also possibly through cel-
lular responses, which contrasts with the IIV-conferred
protection that mainly operates via humoral responses to
the HA and NA surface antigens. Moreover, the different
result for the LAIV vaccine – no evidence of modifica-
tion of LAIV vaccine efficacy by prior vaccination or by
post-vaccination HAI or NAI titer – may strengthen this
point, given that LAIV mimics natural immunity. Given
the limited precision in the analysis, it would be important
to confirm the effect modification findings in other stud-
ies. A caveat of this study was that data were not collected
on recent influenza history, nor on recent vaccination,
precluding the ability to study any moderating impact
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Fig. 6 Estimated LAIV VE by Day 30 and fold-rise HAI and NAI titer variables. Estimated VE by a Day 30 HAI titer if assigned vaccine, b fold-rise in HAI
titer if assigned vaccine, c Day 30 NAI titer if assigned vaccine, d fold-rise in NAI titer if assigned vaccine. Each solid black line is the estimated VE by
the Juraska (2018) method [48]. Dashed and dot-dashed black lines are pointwise and simultaneous 95% confidence intervals, respectively. Each
dotted red line is the estimated overall VE. P-values shown are 2-sided p-values for effect modification
of recent natural or vaccine immunity on the HAI/NAI
correlates of risk and of vaccine efficacy.
IIV efficacy significantly increased within strata of
increasing Day 30 NAI titers observed for vaccinated indi-
viduals and predicted counterfactually for placebo recip-
ients, and similarly seemed to increase with Day 30 HAI
titers. In terms of point estimates, LAIV efficacy trended
toward decreasing with both Day 30 NAI titers and Day
30 HAI titers, but with inadequate precision to infer a real
decrease – overall there was no statistical evidence that
LAIV efficacy correlated with any post-vaccination titer
markers.
Mathematical modeling has been one approach to try
to quantify the relationship between HAI titer and VE
[3]. Such modeling has predicted that vaccines that elicit
higher HAI responses should have higher VE against
laboratory-confirmed influenza disease [52]. Influenza
vaccine efficacy studies have also supported that post-
vaccination HAI titers are positively associated with VE
[12, 51, 53], although it has been proposed that such
titers should not be used as a surrogate endpoint for
reliably inferring VE due to the potential importance of
cell-mediated immunity and anti-NA antibodies [12, 14].
Using the Prentice (1989) [54] surrogate endpoint frame-
work with Dunning et al.’s (2015) scaled-logit model [55],
Dunning et al. (2016) [56] analyzed a trial of the IIV vac-
cine at standard dose (as in FLUVACS) vs. high dose
in persons 65 years of age and older and inferred that
post-vaccinationHAI titer of 40 corresponded to 50% pro-
tection (identical for vaccine- and natural-immunity for a
valid Prentice surrogate) when the assay virus was anti-
genically well-matched to the circulating virus. Based on
our VE moderation framework applied to FLUVACS, an
HAI titer of 40 corresponded to estimated IIV VE of about
55% and an NAI titer of 40 corresponded to estimated VE
of about 55-60% (Fig. 5), remarkably close to the previ-
ous estimates. Thus, use of the VEmoderation framework
may provide some additional confirmation that a post-
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vaccination titer response above 40 predicts reasonably
high vaccine protection, complementing the result from
the Prentice approach. As Dunning et al. did not analyze
whether or how post-vaccination HAI fold-rise in titer
corresponded to protection, the relative performance of
post-vaccination absolute titer vs. fold-rise as correlates of
protection in this framework cannot be compared.
The pattern of estimated VE as a function of Day 30
HAI titer in vaccinees was similar to that of the pattern
with Day 30 NAI titer, and the analysis did not pro-
vide statistical support that one marker was a stronger
correlate of VE. While our analysis lacked the statisti-
cal precision to discern which correlate was stronger, the
fact that the point estimates showed a stronger associa-
tion for NAI titer may suggest that NAI is as important
as HAI. Had the association patterns been largely dif-
ferent by assay the study could have detected it– future
studies with greater power would be needed to detect
small-to-moderate differences. In addition, our inability
to distinguish the predictive power of HAI and NAI titers
may have been impeded to some degree by the modest
correlation between these two antibody measures. Future
studies could also assess how vaccine efficacy depends
jointly on HAI and NAI titer levels, as there was insuffi-
cient sample size to support these analyses in the present
study.
We next discuss some limitations of this work. First,
as influenza vaccination was specifically recommended
to individuals aged ≥50 years [57], ethical considerations
precluded the enrollment of such individuals in the study,
given that some of these individuals would have been
randomized to placebo. Thus, we were unable to exam-
ine whether our findings held true in older individuals.
This is an ongoing issue for all clinical trials of influenza
vaccines, given the current recommendations. Given the
evidence that T-cell responses may be a better correlate of
protection against influenza disease than antibody titers
in the elderly (≥65 years; reviewed in [58]), it is reason-
able to hypothesize that we may see differences in the
associations of HAI and/or NAI titer with VE, particu-
larly in the elderly; however, there are considerable ethical
and methodological challenges involved in testing this
hypothesis.
In addition, a limitation of the VE moderation statis-
tical methods used here is that they could give biased
results if certain assumptions are violated [40, 46]. The
methods assume that within each treatment arm the risk
of the influenza endpoint conditional on the baseline
and post-baseline biomarker follows a regression model,
which can be directly checked. However, the methods
also assume that, for placebo recipients, after conditioning
on baseline demographic variables and the baseline and
post-baseline biomarker values, influenza risk does not
depend on the post-baseline biomarker value that would
have been observed had the placebo recipient been vac-
cinated – this assumption cannot be validated because
the vaccine response biomarker is counterfactual/missing.
Undiagnosable violations of this assumption could cause
bias in the estimated VE curves. A common mispercep-
tion is that the VE moderation methods require perfect
prediction of the counterfactual vaccine responses for
placebo recipients; in fact, the methods were designed to
account for uncertainty in the prediction and have been
shown to provide valid results with partial predictiveness.
Another limitation of our analysis is that there were too-
few influenza events to estimate VE by post-vaccination
titer curves separately for the previously vaccinated and
the previously unvaccinated. Given the significant inter-
action result that Day 0 NAI positively associated with
IIV VE in the previously vaccinated yet negatively asso-
ciated with IIV VE in the previously unvaccinated, and
the positive association of Day 0 and Day 30 titers, we
conjecture that the positive association of Day 30 titers
with IIV VE may have been driven by the previously vac-
cinated subgroup. The design of future studies should
consider planning for the enablement of such analyses
with adequate statistical power.
Conclusions
Our results suggest that future vaccine development
efforts may consider prioritizing post-vaccination titer
endpoints as criteria for screening and advancement of
candidate vaccines, as better correlates of VE than fold-
rise in titers. Moreover, they imply that for individuals
with high HAI or NAI titers when the influenza season
begins and who were not previously vaccinated, inacti-
vated vaccination may be unlikely to confer protection
beyond that already present due to natural immunity
and/or immunity from previous vaccinations. Acknowl-
edging the limited precision of the data set for study-
ing moderators of vaccine efficacy, perhaps the most
important conclusion is that in future vaccine efficacy
trials it is critical to measure both baseline and post-
vaccination titers, in both vaccinated and placebo recip-
ients, to enable adequately precise estimation of the
VE-by-postvaccination-response curves by leveraging the
correlation of the Day 0 and Day 30 titers. Other baseline
measurements could also help improve the precision in
estimating the correlates of vaccine efficacy [59]. Few effi-
cacy trials have measured the requisite data for estimat-
ing VE-by-postvaccination-response curves; an important
conclusion is that future studies should plan such mea-
surements.
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